- Home
- XAIR vs BLRX Comparison
XAIR vs BLRX Comparison
Compare XAIR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- BLRX
- Stock Information
- Founded
- XAIR 2011
- BLRX 2003
- Country
- XAIR United States
- BLRX Israel
- Employees
- XAIR N/A
- BLRX N/A
- Industry
- XAIR Medical/Dental Instruments
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- BLRX Health Care
- Exchange
- XAIR Nasdaq
- BLRX Nasdaq
- Market Cap
- XAIR 33.6M
- BLRX 36.0M
- IPO Year
- XAIR N/A
- BLRX 2011
- Fundamental
- Price
- XAIR $0.46
- BLRX $0.20
- Analyst Decision
- XAIR Strong Buy
- BLRX Strong Buy
- Analyst Count
- XAIR 4
- BLRX 2
- Target Price
- XAIR $3.67
- BLRX $5.50
- AVG Volume (30 Days)
- XAIR 731.9K
- BLRX 2.2M
- Earning Date
- XAIR 02-10-2025
- BLRX 11-25-2024
- Dividend Yield
- XAIR N/A
- BLRX N/A
- EPS Growth
- XAIR N/A
- BLRX N/A
- EPS
- XAIR N/A
- BLRX N/A
- Revenue
- XAIR $2,342,000.00
- BLRX $21,991,000.00
- Revenue This Year
- XAIR $230.80
- BLRX N/A
- Revenue Next Year
- XAIR $265.55
- BLRX N/A
- P/E Ratio
- XAIR N/A
- BLRX N/A
- Revenue Growth
- XAIR 685.91
- BLRX N/A
- 52 Week Low
- XAIR $0.30
- BLRX $0.19
- 52 Week High
- XAIR $2.36
- BLRX $1.70
- Technical
- Relative Strength Index (RSI)
- XAIR 47.58
- BLRX 24.20
- Support Level
- XAIR $0.44
- BLRX $0.23
- Resistance Level
- XAIR $0.50
- BLRX $0.56
- Average True Range (ATR)
- XAIR 0.04
- BLRX 0.03
- MACD
- XAIR -0.01
- BLRX -0.00
- Stochastic Oscillator
- XAIR 25.36
- BLRX 7.26
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.